Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2015 1
2017 1
2018 3
2019 1
2020 9
2021 7
2022 13
2023 13
2024 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
MOG antibody-associated optic neuritis.
Jeyakumar N, Lerch M, Dale RC, Ramanathan S. Jeyakumar N, et al. Eye (Lond). 2024 Aug;38(12):2289-2301. doi: 10.1038/s41433-024-03108-y. Epub 2024 May 23. Eye (Lond). 2024. PMID: 38783085 Free PMC article. Review.
Long-Term Cardiovascular Outcomes in Children and Adolescents With Hypertension.
Robinson CH, Hussain J, Jeyakumar N, Smith G, Birken CS, Dart A, Dionne J, Garg A, Kandasamy S, Karam S, Marjerrison S, South AM, Thabane L, Wahi G, Zappitelli M, Chanchlani R. Robinson CH, et al. Among authors: jeyakumar n. JAMA Pediatr. 2024 Jul 1;178(7):688-698. doi: 10.1001/jamapediatrics.2024.1543. JAMA Pediatr. 2024. PMID: 38709137
Authors' Reply.
Robinson CH, Jeyakumar N, Wald R, Zappitelli M, Chanchlani R. Robinson CH, et al. Among authors: jeyakumar n. J Am Soc Nephrol. 2021 Oct;32(10):2681-2682. doi: 10.1681/ASN.2021060879. Epub 2021 Sep 16. J Am Soc Nephrol. 2021. PMID: 34531178 Free PMC article. No abstract available.
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Srinagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs A, Moon J, Baggott C, Arai S, Bharadwaj S, Johnston LJ, Liedtke M, Lowsky R, Meyer E, Negrin R, Rezvani A, Shizuru J, Sidana S, Egeler E, Mavroukakis S, Tunuguntla R, Gkitsas-Long N, Retherford A, Brown AK, Gramstrap-Petersen AL, Ibañez RM, Feldman SA, Miklos DB, Mackall CL, Davis KL, Frank M, Ramakrishna S, Muffly L. Schultz LM, et al. Among authors: jeyakumar n. Leukemia. 2024 May;38(5):963-968. doi: 10.1038/s41375-024-02220-y. Epub 2024 Mar 15. Leukemia. 2024. PMID: 38491306 Clinical Trial.
Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury.
Robinson CH, Jeyakumar N, Luo B, Askenazi D, Deep A, Garg AX, Goldstein S, Greenberg JH, Mammen C, Nash DM, Parekh RS, Silver SA, Thabane L, Wald R, Zappitelli M, Chanchlani R. Robinson CH, et al. Among authors: jeyakumar n. J Am Soc Nephrol. 2024 Nov 1;35(11):1520-1532. doi: 10.1681/ASN.0000000000000445. Epub 2024 Jul 17. J Am Soc Nephrol. 2024. PMID: 39018120
Monogenic lupus - from gene to targeted therapy.
Menzel K, Novotna K, Jeyakumar N, Wolf C, Lee-Kirsch MA. Menzel K, et al. Among authors: jeyakumar n. Mol Cell Pediatr. 2024 Sep 12;11(1):8. doi: 10.1186/s40348-024-00181-x. Mol Cell Pediatr. 2024. PMID: 39264482 Free PMC article. Review.
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. Srinagesh H, et al. Among authors: jeyakumar n. Blood. 2024 Oct 17;144(16):1689-1698. doi: 10.1182/blood.2024024952. Blood. 2024. PMID: 38968138 Clinical Trial.
Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.
Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Aldoss I, et al. Among authors: jeyakumar n. Blood Adv. 2024 Aug 2:bloodadvances.2024013747. doi: 10.1182/bloodadvances.2024013747. Online ahead of print. Blood Adv. 2024. PMID: 39093952
56 results